Neurocrine Biosciences Stock News

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conference Call and Webcast Scheduled for Wednesday, May 4 SAN DIEGO , April 13, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarte

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 5 0 0

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

SAN DIEGO , March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patien

Sector ETF report for FBT

Smart Beta ETF report for FBT

Piper Sandler has downgraded Neurocrine Biosciences (NBIX) to neutral from overweight amid concerns of more modest long-term growth of its tardive dyskinesia treatment Ingrezza.

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago q

NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day.

Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates

Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 4 0 0

Neurocrine Biosciences (NASDAQ: NBIX ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 2 0 0 2M Ago 0 1 2 0 0 3M Ago 1 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $110.75 with a high of $154.00 and a low of $90.00. Below is a summary of how these 8 analysts rated Neurocrine Biosciences over the past … Full story available on Benzinga.com

Goldman Sachs has upgraded shares of Neurocrine Biosciences (NBIX) to buy from hold based on its solid balance sheet and catalysts coming in the next 12-18 months.